Dear Colleagues,

Lifestyle interventions, pharmacological treatment—including lipid-lowering, antidiabetic, anti-hypertensive, and antithrombotic interventions—are an unquestionable and major success in modern medicine, contributing to the worldwide increase in life expectancy by preventing cardiometabolic disease. However, aging populations represent a major challenge for healthcare providers, since they are a major limitation of the current strategies for cardiometabolic disease management in the elderly. Epidemiological studies have shown the complex and age-driven etiology of cardiometabolic diseases by identifying many risk factors. Genetics has a key role in cardiometabolic diseases by affecting composition and functionality of lipoproteins, intracellular lipid metabolism, and inflammation. Translational research has been very successful in the creation of multidisciplinary approaches to the understanding of cardiometabolic diseases. Unfortunately, pathobiological research has not been equally successful in translating biological insights into prevention, diagnosis, and treatment of human diseases. The limited amount of success can be explained by the gaps between clinically relevant questions, preclinical models, and technologies, as well as by conventional reductionist approaches. Future research strategies should create the basis for shifting the healthcare management of cardiometabolic disease from diagnosis and treatment to prevention. An integrated approach (e.g., network medicine), with a coordinated, unifying, multidisciplinary platform in which genomic, epigenomic, molecular, and clinical data are shared will enable a more efficient understanding of the pathogenic processes underlying cardiometabolic diseases and lead to a better comprehension of the drivers for healthy aging across the life course. 

This Special Issue welcomes the submission of original research and review manuscripts on prevention, diagnosis, and therapy of cardiometabolic diseases focusing on aging, lipoprotein, and intracellular lipid metabolism, and integrated approach of different omics analyses. The overall aim of the Special Issue is to achieve a realistic overview of this exciting and interdisciplinary field of biomedical research on cardiometabolic diseases.

Prof. Dr. Paolo Parini
Prof. Dr. Ewa Ehrenborg
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• aging
• autophagy
• atherosclerosis
• cardiometabolic diseases
• epigenomic
• genomic
• GWAS
• lipid
• lipoprotein metabolism
• metabolomic
• metagenomic network medicine
• proteomic